26 October 2020
2 min read
EU-CardioRNA COST Action: LIH plays a leading role in international collaborative research on heart disease
The LIH is not only a privileged research partner in Luxembourg, but also worldwide as a lead institution in large-scale collaborative initiatives. One of the most recent examples is the EU-CardioRNA COST Action CA17129 (EU-CardioRNA - www.cardiorna.eu), which aims to understand the complex role of transcriptomics in cardiovascular disease.
Founded at the end of 2018, the EU-CardioRNA network just celebrated its second anniversary. It includes 180 members from 36 European and partner countries. The collaborative network brings together academic researchers, clinicians, and industrial partners with multidisciplinary expertise ranging from basic research to clinical research and molecular diagnostics, from pharmacology to molecular biology and many other aspects of biology, from information technology to bioinformatics, biostatistics, and artificial intelligence.
Cardiovascular disease remains a major cause of mortality
Potential of RNA molecules in diagnosing and treating patients
Transcriptomics Research to Improve Cardiovascular Healthcare. The EU-CardioRNA COST Action. Lina Badimon, Yvan Devaux, European Heart Journal, Volume 41, Issue 35, 14 September 2020, Pages 3296–3298